A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN)

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.450 enrolled

Overview

A study of pregabalin efficacy and safety in a racially and culturally diverse group of subjects with painful diabetic peripheral neuropathy (DPN).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

450

Conditions

Diabetic Neuropathy, Painful

Interventions

pregabalinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of Type 1 or 2 diabetes mellitus. * Diagnosis of painful DPN for at least 12 months but less than 5 years in duration. Exclusion Criteria: * Neurologic Disorders unrelated to diabetic neuropathy that may confuse or confound the assessment of neuropathic pain. * Presence of any severe pain associated with conditions other than DPN that may confuse or confound the assessment of neuropathic pain.

Locations (35)

Outcomes

Primary Outcomes

Mean pain score

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

Buenos Aires, Argentina

Pfizer Investigational Site

Belo Horizonte, Minas Gerais, Brazil

Pfizer Investigational Site

Niterói, Rio de Janeiro, Brazil

Pfizer Investigational Site

Providencia, Santiago Metropolitan, Chile

Pfizer Investigational Site

Valparaíso, Valparaiso, Chile

Pfizer Investigational Site

Medellín, Antioquia, Colombia

Pfizer Investigational Site

Bogotá, Cundinamarca, Colombia

Pfizer Investigational Site

Quito, Pichincha, Ecuador

Pfizer Investigational Site

Jakarta Pusat, Indonesia

Pfizer Investigational Site

Surabaya, Indonesia

...and 25 more locations